AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06747169
Drug: Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients were treated with a combination therapy consisting of sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin. The study is designed to assess the efficacy and safety of this treatment regimen in the specified population.
Trial: NCT06748014
Drug: Aescin in Horse Chestnut
RxNorm normalized name: aescin in horse chestnut
DrugBank: Horse chestnut (DB13195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month
Trial: NCT06748404
Drug: Tricalm Hydrogel
RxNorm normalized name: ALUMINUM ACETATE 2 mg in 1 mL TOPICAL GEL [TriCalm Hydrogel]
DrugBank: Aluminum acetate (DB14518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TriCalm Hydrogel® is a topical gel that allows rapid administration to areas of the skin. TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.
Trial: NCT06748404
Drug: Triamcinolone acetonide 0.1% cream
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 0.1% CREAM
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% cream is a topical steroid cream that will be applied directly to the skin.
Trial: NCT06747468
Drug: Avexitide
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
Trial: NCT06741982
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV Q3W
Trial: NCT06741982
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30mg PO QD
Trial: NCT06754410
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group A take tamsulosin once daily
Trial: NCT06754410
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: give cetirizine once dailly
Trial: NCT06752720
Drug: Stem cell Transplantation
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured autologous mescenchymal stem cell (HUNS001-01) in our cell processing center will be injected into the brain, totally 4 x 10\^7 cells, in 2 brain sites.
Trial: NCT06760117
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.
Trial: NCT06760117
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ：100mg/m2/d，d1-5
Trial: NCT06760117
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VCR: 1.5mg/m2/d(≯2mg), d1
Trial: NCT06223568
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.
Trial: NCT06223568
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.
Trial: NCT06223568
Drug: PRGN-2009
RxNorm normalized name: PRGN-3006
DrugBank: PRGN-3006 (DB17229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
Trial: NCT06603246
Drug: GDC-6988
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-6988 will be administered using a dry powder inhalation
Trial: NCT06454669
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
Trial: NCT06533826
Drug: Trastuzumab Deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.
Trial: NCT06533826
Drug: Datopotamab Deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.
Trial: NCT04566887
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as 100mg tablets.
Trial: NCT06753526
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For 1st group of patients
Trial: NCT06753526
Drug: Tamsulosin 0.4 mg QD
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group 3 by once per day
Trial: NCT05175235
Drug: Nivolumab, Pembrolizumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
Trial: NCT06776770
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.~Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.~XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1\~14.
Trial: NCT05605496
Drug: NP137
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion, 14mg/kg, Q3W
Trial: NCT05732831
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An anti PD-1 antibody, will be administered intravenously
Trial: NCT06626230
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin C3 Complex powder: Curcuma longa (Turmeric), a constituent of the spice turmeric, is considered a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert the curcumin capsules gelatin intra-anally every day for a 14-day treatment period.~Escalating doses
Trial: NCT05725876
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.
Trial: NCT06780150
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
Trial: NCT06757335
Drug: HP568
RxNorm normalized name: Hydrocodone Bitartrate and Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the I/II stage: HP568 administered QD or BID for 28 day cycles.
Trial: NCT06757335
Drug: HP568 in combination with palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
Trial: NCT06750952
Drug: Ivonescimab Combined With Chemotherapy
RxNorm normalized name: miconazole
DrugBank: Ivonescimab (DB18931)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ivonescimab injection is an IgG1 subtype humanized bispecific antibody targeting human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1). It can bind to VEGF-A and PD-1 at the same time, and competitively block the interaction between VEGF-A, PD-1 and their ligands, exerting antitumor activity.
Trial: NCT05131100
Drug: Somavert
RxNorm normalized name: Somavert
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As provided in real world practice
Trial: NCT06746064
Drug: CHF10073 (Part 1 - SAD)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of CHF10073 for each cohort
Trial: NCT06746064
Drug: CHF10073 (Part 2 - MAD)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of CHF10073 for each cohort
Trial: NCT06746064
Drug: CHF10073 (Part 3)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of CHF10073
Trial: NCT06771544
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT06773767
Drug: 150 mg trazodone hydrochloride
RxNorm normalized name: trazodone hydrochloride 150 MG
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.
Trial: NCT06773767
Drug: 300 mg trazodone hydrochloride
RxNorm normalized name: trazodone hydrochloride 300 MG
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state
Trial: NCT06772272
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) used to treat anemia. Participants in the Roxadustat group will receive 100mg of Roxadustat orally three times per week for three weeks (two weeks prior to surgery and one week post-surgery). The dosage may be adjusted based on hemoglobin levels during the perioperative period: if hemoglobin rises above 150g/L, the drug will be stopped; if hemoglobin increases by more than 20g/L from baseline but is still below 130g/L, the dosage will be reduced to 70mg; if hemoglobin drops by more than 20g/L from baseline, the dosage will be increased to 120mg.
Trial: NCT05905341
Drug: PF-07224826
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
Trial: NCT06751940
Drug: Neoantigen-loaded DC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT06777433
Drug: RAD101 (18F-FPIA)
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
Trial: NCT06765161
Drug: efgartigimod administration
RxNorm normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: efgartigimod infusion
Trial: NCT06742528
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.
Trial: NCT06742528
Drug: Iron Polymaltose Complex
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
Trial: NCT06775483
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously according to protocol.
Trial: NCT06750783
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.
Trial: NCT06750653
Drug: Vaseline
RxNorm normalized name: Vaseline
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaseline is a formulation of active ingredient white petrolatum, USP (100%), manufactured by Unilever, for topical skin use.
Trial: NCT06776445
Drug: gabapentin 300mg bid
RxNorm normalized name: gabapentin 300 MG
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
Trial: NCT06776445
Drug: gabapentin 300mg tid
RxNorm normalized name: gabapentin 300 MG
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
Trial: NCT06549595
Drug: BR
RxNorm normalized name: bran
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine, Rituximab
Trial: NCT05909995
Drug: INCB 99280 with Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation and expansion of INCB 99280 with Ipilimumab
Trial: NCT04886258
Drug: DFV890
RxNorm normalized name: DFV890
DrugBank: DFV890 (DB16461)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFV890
Trial: NCT06757738
Drug: TRX-100
RxNorm normalized name: TRX-0237
DrugBank: Hydromethylthionine mesylate (DB16899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEN inhibitor, dosage form - capsules, dosing regimen - QD
Trial: NCT06749899
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
Trial: NCT06749899
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
Trial: NCT06749899
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Trial: NCT04925479
Drug: Asciminib Pediatric formulation group
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)
Trial: NCT04925479
Drug: Asciminib Adult formulation group
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally.
Trial: NCT06739707
Drug: MD-18
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
Trial: NCT06638307
Drug: Elacestrant
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elacestrant administered as oral tablets.
Trial: NCT06777628
Drug: Immunochemotherapy combined with antiangiogenic
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immunochemotherapy combined with antiangiogenic
Trial: NCT06773351
Drug: Sevoflurane 0 + different doses of ciprofol
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 0% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.6mg/kg, respectively.
Trial: NCT06773351
Drug: Sevoflurane 0.7% + different doses of ciprofol
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 0.7% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.5mg/kg, respectively.
Trial: NCT06773351
Drug: Sevoflurane 1.0% + different doses of ciprofol 0.05
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 1.0% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
Trial: NCT06773351
Drug: Sevoflurane 1.5% + differnet doses of ciprofol
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 1.5% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
Trial: NCT06773351
Drug: Sevoflurane 2.0% + different doses of ciprofol
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 2.0% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
Trial: NCT06773351
Drug: Sevoflurane 2.5% + different doses of ciprofol
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 2.5% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
Trial: NCT06773351
Drug: Ciprofol 0 + different end-expiratory concentration of sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofol 0 combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5%, respectively.
Trial: NCT06773351
Drug: Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofol 0.1mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
Trial: NCT06773351
Drug: Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofol 0.2 mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
Trial: NCT06773351
Drug: Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofol 0.3 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
Trial: NCT06773351
Drug: Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofol 0.4 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
Trial: NCT06614192
Drug: ABBV-400
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT06614192
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT06769048
Drug: BI 1584862
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1584862